Telix Pharmaceuticals Limited (TLX) has submitted a marketing authorizationapplication in Europe for TLX101-Px, its glioma imaging candidate. The submission covers major European markets. The company noted that submission of the U.S. New Drug Application will follow.
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said: "We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.